Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 33

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 33
---
18.7 million, a decrease of $6.7 million compared to $25.4 million for the corresponding period in 2024. Our effective tax rate was 26.2% for the three months ended June 28, 2025 compared to 21.2% for the corresponding period in 2024. The tax rate increase was primarily attributable to the tax effects from stock-based compensation deductions, as well as non-taxable remeasurement gains on a previous equity investment in Noveprim during the three months ended June 29, 2024.

31 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Six Months Ended June 28, 2025 Compared to Six Months Ended June 29, 2024

Revenue and Operating Income

The following tables present consolidated revenue by type and by reportable segment:

Six Months EndedJune 28, 2025June 29, 2024$ change% change(in thousands, except percentages)Service revenue$1,638,759 $1,659,762 $(21,003)(1.3)%Product revenue377,544 377,915 (371)(0.1)%Total revenue$2,016,303 $2,037,677 $(21,374)(1.0)%

Six Months EndedJune 28, 2025June 29, 2024$ change% changeImpact of FX(in thousands, except percentages)RMS$426,344 $427,296 $(952)(0.2)%— %DSA1,210,638 1,232,871 (22,233)(1.8)%0.2 %Manufacturing379,321 377,510 1,811 0.5 %0.1 %Total revenue$2,016,303 $2,037,677 $(21,374)(1.0)%0.2 %

The following table presents operating income by reportable segment:

Six Months EndedJune 28, 2025June 29, 2024$ change% changeImpact of FX(in thousands, except percentages)RMS$79,391 $73,097 $6,294 8.6 %(0.2)%DSA216,733 253,215 (36,482)(14.4)%1.9 %Manufacturing3,441 70,911 (67,470)(95.1)%(0